Generated using OpenAI Deep Research API
SFT2D3 encodes a vesicle-transport membrane protein that is involved in intracellular trafficking. It is predicted to function in protein transport and vesicle-mediated trafficking (www.ncbi.nlm.nih.gov). In particular, SFT2D3 (also known as vesicle transport protein SFT2C) may facilitate the fusion of retrograde transport vesicles from endosomal compartments to the Golgi apparatus (www.genecards.org). This suggests a role in the endosome-to-Golgi retrieval pathway, where it could help target or tether incoming vesicles for fusion with Golgi membranes. Although the precise molecular mechanism remains under investigation, evidence from related proteins indicates SFT2D3 likely acts as a SNARE-associated factor. In yeast, the Sft2 protein (homologous to SFT2D3) genetically interacts with the Golgi t-SNARE Sed5 and is required for efficient SNARE recycling to the Golgi (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Similarly, the mammalian SFT2 family has been implicated in maintaining proper SNARE localization: knockdown of the paralog SFT2D2 disrupts the trafficking of Golgi SNAREs and endosomal cargos, supporting the idea that SFT2 proteins promote vesicle fusion at the trans-Golgi network (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Therefore, while SFT2D3 itself is less characterized experimentally, it is believed to operate as a membrane trafficking factor that ensures vesicles deliver their cargo to the correct Golgi subcompartment, possibly by organizing or stabilizing SNARE complexes during vesicle fusion.
SFT2D3 is an integral membrane protein localized to intracellular organelles of the secretory and endocytic pathways. It is predicted to reside in the endomembrane system, particularly on intracellular membrane-bound organelles (www.ncbi.nlm.nih.gov). Functional context and homology suggest a more specific localization to the Golgi apparatus and associated vesicular structures. In yeast, Sft2p predominantly localizes to the late Golgi (trans-Golgi network), and mammalian SFT2D2 was observed on perinuclear Golgi membranes and endosomes positive for the retromer protein VPS35 (pmc.ncbi.nlm.nih.gov). By analogy, SFT2D3 is expected to be found at the Golgi complex (likely the trans-Golgi) and on recycling endosomes that shuttle proteins back to the Golgi. Consistent with a membrane localization, SFT2D3 is predicted to span the lipid bilayer multiple times (see below), with cytoplasm-facing N- and C-termini that could interact with cytosolic trafficking machinery (pmc.ncbi.nlm.nih.gov). Alliance and UniProt annotations similarly place SFT2D3 in the cytoplasm and membranes of organelles (www.ncbi.nlm.nih.gov), reinforcing that it is not a secreted protein but rather anchored within cellular membranes. No experimental immunolocalization for SFT2D3 in human cells has been published to date, but its family’s behavior suggests it concentrates in the Golgi/TGN region and possibly endosomal vesicles, consistent with a role in retrograde vesicle fusion at the Golgi.
SFT2D3 is involved in key intracellular biological processes related to vesicle trafficking. Gene Ontology annotations predict involvement in “protein transport” (GO:0015031) and “vesicle-mediated transport” (GO:0016192) (www.ncbi.nlm.nih.gov). More specifically, SFT2D3 is thought to function in the retrograde transport from endosomes to the Golgi (a subset of vesicle-mediated transport). This retrograde pathway retrieves proteins such as sorting receptors (e.g. mannose-6-phosphate receptor) from endosomes back to the Golgi, and is vital for recycling of membrane proteins and maintaining Golgi function (pmc.ncbi.nlm.nih.gov). SFT2D3’s UniProt description highlights fusion of endosome-derived vesicles with the Golgi as its putative role (www.genecards.org), which aligns with the biological process “retrograde transport, endosome to Golgi” (GO:0042147). By aiding vesicle fusion or SNARE recycling at the trans-Golgi, SFT2D3 helps ensure that Golgi-resident enzymes and sorting receptors are correctly recycled – a process essential for normal lysosomal enzyme targeting and other cellular logistics (pmc.ncbi.nlm.nih.gov). In yeast, the Sft2 protein and its partner Got1 work redundantly to facilitate vesicle fusion with Golgi membranes (pmc.ncbi.nlm.nih.gov), implying that the human SFT2D3 likely contributes to analogous processes in higher eukaryotes. Overall, SFT2D3 is part of the vesicle trafficking machinery, particularly impacting endomembrane transport pathways such as endosome-to-Golgi retrieval and possibly intra-Golgi vesicle traffic.
The SFT2D3 protein contains a conserved SFT2 (Got1) domain that characterizes the Got1/Sft2 family of vesicle transport proteins. This domain (Pfam pfam04178) spans roughly amino acids 87–172 of SFT2D3 (www.ncbi.nlm.nih.gov). It is a hydrophobic domain comprising multiple transmembrane segments. Like other SFT2 family members, SFT2D3 is predicted to be a tetra-span transmembrane protein, meaning it has four α-helical transmembrane domains (pmc.ncbi.nlm.nih.gov). These likely form a compact membrane-embedded structure with short luminal and cytosolic loops. Both the N-terminus and C-terminus of SFT2D3 are predicted to face the cytosol (due to an even number of membrane spans). There are no known enzymatic active sites or large globular domains – the protein is primarily defined by its transmembrane architecture. TMD-based topology suggests SFT2D3 might form a small channel-like or receptor-like structure within the Golgi/endosome membranes, possibly serving as a scaffold or organizer for other proteins. SFT2D3 belongs to the SFT2 family, which in humans includes paralogs SFT2D1, SFT2D2, and SFT2D3 that all share the core Got1/Sft2 domain (pmc.ncbi.nlm.nih.gov). This family is conserved across eukaryotes; the defining structural feature is the four transmembrane helices that are critical for its role in membrane fusion events. No high-resolution structure is currently available for SFT2D3, but the strong sequence conservation of the SFT2 domain implies a preserved structure and function. Notably, a related human protein (SFT2D2) was shown to be palmitoylated by the Golgi-localized palmitoyltransferase ZDHHC5 (pmc.ncbi.nlm.nih.gov), suggesting that SFT2D3 might also undergo lipid modification (palmitoylation) to fine-tune its membrane association or sub-compartment localization. This post-translational modification would further anchor SFT2D3 in Golgi membranes and potentially regulate its interactions. In summary, SFT2D3 is a small integral membrane protein with four transmembrane domains and belongs to a conserved family of vesicle fusion facilitators (Got1/Sft2-like proteins) (www.ncbi.nlm.nih.gov).
Expression of SFT2D3 appears to be ubiquitous at low to moderate levels across tissues. According to RNA profiles, SFT2D3 has low tissue specificity, meaning it is expressed in many tissue types rather than being restricted to a particular organ or cell type (www.proteinatlas.org). Its expression clusters with genes involved in general secretory pathway functions (e.g. glycosylation), indicating SFT2D3 is part of the basic cellular machinery active in most cells (www.proteinatlas.org). Consistently, the Human Protein Atlas reports “low cell type specificity” for SFT2D3, and it is detected in a broad range of cell types (www.proteinatlas.org). Notably, SFT2D3 is not detectable in the adult human brain at the RNA level (www.proteinatlas.org), suggesting either very low neuronal expression or technical lack of detection in that tissue. In immune cells, SFT2D3 is also not significantly expressed (www.proteinatlas.org). One single-cell RNA sequencing analysis pointed to dendritic cells as having some SFT2D3 expression (www.proteinatlas.org), but again not uniquely high. Thus, SFT2D3 seems to function as a housekeeping vesicle transport factor present in most secretory cells rather than a specialized or inducible gene. There is no detailed information on transcriptional regulation of SFT2D3 published – it does not belong to a known inducible pathway and likely is constitutively expressed given its fundamental role in trafficking. At the protein level, evidence for SFT2D3 protein expression has been confirmed (classified as “evidence at protein level”) (www.proteinatlas.org), though specific protein quantification or visualization by immunohistochemistry is not available (no tissue immunostaining data). In cancer datasets, SFT2D3 mRNA was found to be group-enriched in certain tumors (notably prostate adenocarcinoma and endometrial carcinoma) (www.proteinatlas.org), possibly reflecting the secretory activity of those tumor cells or tissue-specific upregulation. However, SFT2D3 is not identified as a prognostic marker in cancers (www.proteinatlas.org). Overall, SFT2D3 is broadly expressed at modest levels, consistent with its role in general cellular logistics, and does not exhibit dramatic regulation patterns in normal physiology that have been reported so far.
SFT2D3 is part of an evolutionarily conserved family of membrane trafficking proteins found in eukaryotes from yeast to humans. The SFT2 family originated early in eukaryotic evolution, as evidenced by homologs in fungi, plants, and animals (www.ncbi.nlm.nih.gov). Yeast possesses two analogous proteins: Sft2p and Got1p, which perform related functions in Golgi traffic (pmc.ncbi.nlm.nih.gov). SFT2D3 in humans is one of three paralogous genes (SFT2D1, SFT2D2, SFT2D3) that likely arose from gene duplication events. These human paralogs share homology with yeast Sft2p, although SFT2D3 is more distantly related to yeast Sft2p than SFT2D2 is (SFT2D2 was noted to be partially homologous to yeast Sft2p) (pmc.ncbi.nlm.nih.gov). Nonetheless, key features – such as the four-transmembrane topology and the conserved Got1/Sft2 domain – are present in all species’ versions. In mouse (Mus musculus), the orthologous gene (Sft2d3) is present and highly similar to the human sequence (www.ncbi.nlm.nih.gov). This conservation suggests that the function of SFT2D3 is critical and has been maintained by natural selection. Indeed, across 277 eukaryotic species examined, hundreds of proteins contain the Got1/Sft2 domain, underscoring the broad preservation of this protein family in Metazoa, Fungi, and Plants (www.ncbi.nlm.nih.gov). The strong evolutionary conservation implies that SFT2D3 performs a fundamental cellular role – likely in membrane fusion events – that could not be easily lost without detriment to cellular viability. No prokaryotic homologs exist (consistent with this being a eukaryote-specific trafficking factor) (www.ncbi.nlm.nih.gov). Within the human family, SFT2D1 and SFT2D2 are paralogous proteins that probably have overlapping or redundant functions with SFT2D3 (www.genecards.org). For instance, only combined loss of both yeast Sft2p and Got1p causes strong trafficking defects (pmc.ncbi.nlm.nih.gov), hinting that in mammals the different SFT2 proteins might compensate for one another’s function to some degree. The conservation of SFT2D3 also extends to sequence motifs – critical residues (like cysteines possibly for palmitoylation and charged residues for SNARE interactions) tend to be conserved, reflecting their importance in function (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In summary, SFT2D3 is a highly conserved vesicular transport protein, part of an ancient family central to Golgi and endosomal membrane traffic.
To date, no direct monogenic disorders have been definitively linked to SFT2D3. SFT2D3 is not a well-known disease gene, and there are no reported loss-of-function mutations in humans that cause a characterized genetic syndrome. However, some preliminary or database-driven associations exist. GeneCards and MalaCards list “hereditary retinal dystrophy” as a disease associated with SFT2D3 (www.genecards.org). This suggests that variants in or near SFT2D3 might have been observed in studies of inherited retinal degeneration (a group of disorders like retinitis pigmentosa), or that SFT2D3 lies in a genomic region linked to such a condition. The evidence for this association is currently weak or indirect – SFT2D3 itself has not been reported in peer-reviewed literature as a causative retinal dystrophy gene. It is possible the association arises from high-throughput studies or expression data, since photoreceptors have intense protein trafficking demands and genes involved in vesicle transport (which might include SFT2D3) could impact retinal cell function. Beyond this, no other diseases are strongly connected to SFT2D3. There is interest in the general pathway SFT2D3 operates in: defects in endosome-to-Golgi retrieval are known to contribute to neurodegenerative diseases (for example, retromer complex deficiencies have been linked to Parkinson’s and Alzheimer’s) (pmc.ncbi.nlm.nih.gov). By extension, one could speculate that disruption of SFT2D3 might contribute to cellular stress in neurons or other cells, but this remains unproven. Mouse models can provide clues: a targeted knockout allele of Sft2d3 has been created in mice (www.informatics.jax.org), though detailed phenotypic analysis has not been published, suggesting no gross developmental phenotype was immediately obvious (or it is under study). Cell-based experiments do show that lowering SFT2D2 (a close paralog) impairs receptor recycling to the Golgi (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), which could potentially lead to dysregulation of lysosomal enzyme sorting – a process relevant to some metabolic disorders. So far, SFT2D3 remains a “dark” gene in terms of clinical significance, with no clear loss-of-function human phenotype reported. In cancer, as noted, SFT2D3 does not act as a known oncogene or tumor suppressor, and its expression changes in tumors have not been tied to outcomes (www.proteinatlas.org). In summary, disease associations for SFT2D3 are minimal, with a tentative link to retinal dystrophy in database sources (www.genecards.org) but no confirmed pathology. It is likely that redundancy with SFT2D1/2 masks any severe phenotype of SFT2D3 dysfunction alone, or that subtle cellular defects have yet to be connected to specific diseases.
Because SFT2D3 itself has not been the focus of many individual studies, much of our understanding comes from broader investigations of vesicle transport and from studies on related proteins:
Genome-wide Trafficking Screens: A seminal study by Breusegem & Seaman (2014) performed a genome-wide RNAi screen for factors in endosome-to-Golgi retrieval. They identified SFT2D2 (paralog of SFT2D3) as one of three multipass membrane proteins required for this pathway (pmc.ncbi.nlm.nih.gov). In that study, the authors note that “the mammalian homologs (SFT2D1, SFT2D2, and SFT2D3) are uncharacterized” at the time (pmc.ncbi.nlm.nih.gov). They went on to show that SFT2D2 localizes to perinuclear Golgi and endosomal structures and colocalizes extensively with Golgi SNAREs (especially Syntaxin-6) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Knockdown of SFT2D2 caused mislocalization of a reporter cargo and altered the distribution of certain SNARE proteins (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This provides strong evidence that SFT2 family proteins are directly involved in facilitating endosomal vesicle fusion with the Golgi. By inference, SFT2D3 likely plays a similar role, possibly in overlapping compartments or under specific conditions.
Yeast Studies: The function of SFT2 was first characterized in Saccharomyces cerevisiae. Conchon et al. (1999) identified Sft2p and Got1p as membrane proteins important for traffic to the Golgi, with genetic interactions noted between SFT2 and the Golgi SNARE SED5 (pmc.ncbi.nlm.nih.gov). Deletion of SFT2 alone had mild effects, but combined deletion with GOT1 caused defects in recycling of a v-SNARE (Snc1) to the Golgi (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These findings suggest Sft2p promotes vesicle fusion at the Golgi, in line with later mammalian findings. More recently, Lai et al. (2023) showed that yeast Sft2p acts as a downstream effector of the Arl1-Imh1 GTPase pathway to mediate SNARE recycling under ER stress (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). They demonstrated that Sft2p must be recruited to the late Golgi via Imh1 and that an N-terminal truncation of Sft2p impairs its ability to support SNARE recycling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This detailed mechanism in yeast underscores the importance of Sft2 family proteins in maintaining Golgi SNARE function during stress. While these studies are in yeast, the conservation of SFT2D3 suggests similar principles might apply (e.g. human SFT2 proteins could interact with Arl1 or other golgins for localization).
Proteomic and Interaction Data: High-throughput interaction databases and text-mining have provided limited insight. The Human Protein Atlas mentions that SFT2D3 was found interacting with at least one other protein (www.proteinatlas.org), though the specific partner is not given in the summary. One possibility is an interaction with other Golgi proteins or SNAREs. The STRING database for human SFT2D3 predicts associations with proteins like Golgi transport 1A (GOLT1A) and others in the vesicle transport system (string-db.org). Additionally, it’s known that ZDHHC5 can palmitoylate SFT2D2 and possibly SFT2D3, indicating a biochemical link between SFT2 proteins and palmitoylation enzymes in the Golgi (pmc.ncbi.nlm.nih.gov). No known enzymatic activity or ligand-binding function has been found for SFT2D3; experimental evidence instead points to it working as part of a protein complex in membranes.
Genetic and Genomic Data: SFT2D3’s gene (located on human chromosome 2) has been catalogued in genomic databases. It consists of a small coding sequence (the transcript NM_032740) with a single protein-coding exon in some isoforms. The gene is tagged as “validated” in NCBI RefSeq, indicating high confidence in its sequence and transcript structure (www.ncbi.nlm.nih.gov). Orthologous genes are present in model organisms (e.g., mouse Sft2d3 gene ID 67158, located on mouse chromosome 18) (www.informatics.jax.org). No common single-nucleotide polymorphisms in SFT2D3 are known to have clinical significance, although a few variants are listed with uncertain significance (e.g. a missense A23T noted in ClinVar with no clear phenotype) (www.genecards.org).
In summary, key literature supports a model where SFT2D3 (and its family) act as integral membrane facilitators of vesicle fusion at the Golgi, working in concert with SNARE complexes and trafficking regulators. Experimental evidence from yeast and mammalian cells highlights their role in retrograde vesicle transport and SNARE protein recycling, even though SFT2D3 specifically has not yet been singled out for detailed study. Future research may elucidate SFT2D3’s unique contributions or redundant functions in cells, as well as any links to disease phenotypes.
Based on current knowledge and annotations, the following Gene Ontology (GO) terms are relevant to SFT2D3, reflecting its function, localization, and the processes it is involved in:
Retrograde transport, endosome to Golgi (GO:0042147) – Specific role in returning vesicles from endosomes back to the Golgi (fusion at the TGN) (www.genecards.org).
Cellular Component:
Cytoplasm (GO:0005737) – General cytoplasmic localization, reflecting that it is not in nucleus or secreted (not free in cytosol but associated with cytoplasmic face of organelles) (www.ncbi.nlm.nih.gov).
Molecular Function:
Note: Many molecular function terms are currently inferred or await experimental validation for SFT2D3. The GO annotations for SFT2D3 are mostly based on computational prediction and curator inference (e.g., ISS/IEA evidence from its yeast homolog and general knowledge of vesicle fusion) (www.ncbi.nlm.nih.gov) (www.proteinatlas.org). As research progresses, more specific GO terms (such as those related to SNARE complex regulation or Golgi vesicle fusion) may be added with direct evidence. The above GO terms encapsulate the understanding that SFT2D3 is a membrane-bound vesicle transport facilitator involved in retrograde protein trafficking to the Golgi.
References: The information in this report is derived from gene/protein databases and primary literature. Key sources include the NCBI Gene database and Alliance of Genome Resources summary for SFT2D3 (www.ncbi.nlm.nih.gov), the UniProtKB entry for the human SFT2C protein (www.genecards.org), the Human Protein Atlas for expression and localization data (www.proteinatlas.org) (www.proteinatlas.org), and research studies on the SFT2 family’s role in vesicle trafficking (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Experimental evidence from yeast (e.g., Conchon et al. 1999; Lai et al. 2023) and from mammalian cell screens (Breusegem & Seaman 2014) has been cited to support the functional claims (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These references collectively strengthen the understanding of SFT2D3’s role in Golgi-endosomal transport and its importance as a conserved component of the vesicle fusion machinery.